Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for ACRS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 -62.06M
March 31, 2026 -52.20M
December 31, 2025 -47.11M
September 30, 2025 -42.92M
June 30, 2025 -9.988M
March 31, 2025 -12.32M
December 31, 2024 -20.08M
September 30, 2024 -17.90M
June 30, 2024 -64.46M
March 31, 2024 -72.79M
December 31, 2023 -78.32M
September 30, 2023 -90.68M
June 30, 2023 -73.94M
March 31, 2023 -72.95M
December 31, 2022 -67.57M
September 30, 2022 -65.53M
June 30, 2022 -68.32M
March 31, 2022 -60.87M
December 31, 2021 -52.13M
September 30, 2021 -43.92M
Date Value
June 30, 2021 -45.46M
March 31, 2021 -44.06M
December 31, 2020 -38.63M
September 30, 2020 -50.17M
June 30, 2020 -61.38M
March 31, 2020 -71.93M
December 31, 2019 -96.44M
September 30, 2019 -103.30M
June 30, 2019 -109.80M
March 31, 2019 -110.26M
December 31, 2018 -100.81M
September 30, 2018 -91.77M
June 30, 2018 -75.63M
March 31, 2018 -63.88M
December 31, 2017 -54.66M
September 30, 2017 -44.52M
June 30, 2017 -40.72M
March 31, 2017 -40.37M
December 31, 2016 -34.60M
September 30, 2016 -30.67M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Corcept Therapeutics, Inc. 109.70M
Nektar Therapeutics -233.79M
Xeris Biopharma Holdings, Inc. 56.61M
Alumis, Inc. -351.40M
ANI Pharmaceuticals, Inc. 189.47M